These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32301591)

  • 21. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
    Ball SG; Atkinson S; Sparks J; Bangs M; Goldberger C; Dubé S
    J Clin Psychopharmacol; 2015 Jun; 35(3):266-72. PubMed ID: 25815754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SAMe and sexual functioning.
    Dording CM; Mischoulon D; Shyu I; Alpert JE; Papakostas GI
    Eur Psychiatry; 2012 Aug; 27(6):451-4. PubMed ID: 21398094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
    Clayton AH; Kennedy SH; Edwards JB; Gallipoli S; Reed CR
    J Sex Med; 2013 Oct; 10(10):2465-76. PubMed ID: 23216998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.
    Ozaki N; Otsubo T; Kato M; Higuchi T; Ono H; Kamijima K;
    Psychiatry Clin Neurosci; 2015 Jan; 69(1):34-42. PubMed ID: 24965202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies.
    Nelson JC; Weiller E; Zhang P; Weiss C; Hobart M
    J Affect Disord; 2018 Feb; 227():103-108. PubMed ID: 29055257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Tran P; Skolnick P; Czobor P; Huang NY; Bradshaw M; McKinney A; Fava M
    J Psychiatr Res; 2012 Jan; 46(1):64-71. PubMed ID: 21925682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
    Jain R; Chen D; Edwards J; Mathews M
    Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
    Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
    J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men.
    Fabre LF; Clayton AH; Smith LC; Goldstein I; Derogatis LR
    J Sex Med; 2012 Mar; 9(3):821-9. PubMed ID: 22240272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
    J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-HT2A receptor -1438 G/A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: a prospective exploratory study.
    Liang CS; Ho PS; Chiang KT; Su HC
    J Sex Med; 2012 Aug; 9(8):2009-16. PubMed ID: 22612784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sexual function improves as depressive symptoms decrease during treatment with escitalopram: results of a naturalistic study of patients with major depressive disorder.
    Weber S; Frokjaer VG; Armand S; Nielsen JH; Knudsen GM; Joergensen MB; Stenbaek DS; Giraldi A
    J Sex Med; 2023 Feb; 20(2):161-169. PubMed ID: 36763929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
    Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
    Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.
    Papakostas GI; Mischoulon D; Shyu I; Alpert JE; Fava M
    Am J Psychiatry; 2010 Aug; 167(8):942-8. PubMed ID: 20595412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study.
    Savitz A; Wajs E; Zhang Y; Xu H; Etropolski M; Thase ME; Drevets WC
    Int J Neuropsychopharmacol; 2021 Dec; 24(12):965-976. PubMed ID: 34324636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ
    Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
    Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
    Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.